C4 Therapeutics Announces Positive Data from CFT7455 Phase 1

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Loraine Spreen , Len Reyno , Courtney Solberg , Exchange Commission , International Myeloma Working Group , Therapeutics Inc , Corporate Communications Patient Advocacy , Announces Positive Data , Refractory Multiple , Optimal Dosing Schedule , Well Tolerated , Promising Signs , Immunomodulatory Effects , Novel Multiple Myeloma Agents , Dexamethasone Results , First Two Dose Levels Studied , Multi Refractory Multiple Myeloma , Escalation Continues , Refractory Multiple Myeloma , Complete Phase , Escalation Data Expected , Host Webcast Today , Webcast Link Available , Stable Disease , Partial Response , Stringent Complete Response , Very Good Partial Response , Data Presentations , Eastern Time , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Corporate Communications , Patient Advocacy ,